Back to all News & Events >

Our News

WHRI

MIST (Mindfulness, Incontinence and Sexual function Treatment) Study Research Proposal for a Pilot Study

MIST (Mindfulness, Incontinence and Sexual function Treatment) Study Research Proposal for a Pilot Study Principal Investigators: Dr. Maryse Larouche/Dr. Geoffrey Cundiff Primary Contact: Nicole Koenig, Research Coordinator, 604-806-9829, nkoenig@providencehealth.bc.ca About the study: This study aims to determine if there is an impact on sexual distress using mindfulness-based sex therapy (MBST) in addition to standard urogynecologic care, in women […]

READ MORE
WHRI

Mifepristone Implementation Research in Canada

Mifepristone implementation research in Canada – The CART-Mife Study Principal Investigator: Dr. Wendy Norman Primary Contact: Sarah Munro, Post-doctoral Fellow, 604-875-2424 ext 4990, Sarah.Munro@ubc.ca About the study: Mifepristone, approved by Health Canada, will be introduced in 2017. Currently 96% of Canadian abortions are surgical, largely concentrated in the largest cities close to the southern border. Overcoming […]

READ MORE
WHRI

Canadian Sexual Health Survey Study

Canadian Sexual Health Survey Study Principal Investigators: Dr. Wendy Norman, Dr. Stirling Bryan Primary Contact: Eva McMillan, Research Coordinator, 604-875-2424 x 4871, eva.mcmillan@ubc.ca About the study: This study developed and validated the Canadian Sexual Health Survey (CSHS) that aimed to collect data on sexual and reproductive health among women aged 14-49 years throughout BC. The survey was then […]

READ MORE
WHRI

Better Contraceptive Choices: Insertion timing and effectiveness of intrauterine and other contraceptive methods post-abortion

Better Contraceptive Choices: Insertion timing and effectiveness of intrauterine and other contraceptive methods post-abortion Principal Investigator: Dr. Wendy Norman Primary Contact: Weihong Chen, Research Coordinator, 604-875-2424 x 4894, Weihong.chen@ubc.ca About the study: This project includes two randomized controlled trials:  1) Immediate vs. delayed insertion of intrauterine contraception after second trimester abortion; and, 2) Is FlexiT non-inferior to […]

READ MORE
WHRI

Attitudes and intentions to receive medical and surgical abortions among women seeking pregnancy termination

Principal Investigator: Dr. Brian Fitzsimmons Primary Contact: Nicole Prestley, Research Manager, 604-875-2424 ext 4956, Nicole.Prestley@cw.bc.ca  About the study: Health Canada has recently approved Mifegymiso, a medication which is used around the world for medical termination of pregnancy. In order to understand how the use of this medication will impact Canadian women, WHRI is leading a study […]

READ MORE
WHRI

WHRI Award Winners: UBC Department of OBGYN Academic Day

Congratulations to the WHRI’s Elizabeth McClymont and Dr. Chelsea Elwood for being awarded best Graduate Student and Best Fellow presentations at last Wednesday’s UBC Department of OBGYN Academic Day. Elizabeth McClymont, a Master’s student in Reproductive Sciences working with supervisor Dr. Deborah Money, received the Best Graduate Student award for her presentation, “Two-Year Efficacy of the […]

READ MORE
WHRI

International Women’s Day Event #BeBoldForChange

Last Wednesday, March 8th, the Women’s Health Research Institute hosted an event to celebrate International Women’s Day. This free event was open to the public with presentations from a panel of experts in women’s health who shared the latest recommendations for a variety of health topics. Events such as these are crucial in empowering women […]

READ MORE
WHRI

New WHRI Grant Facilitation Services

The WHRI is excited to announce that we have partnered with the Research and Technology Development Office (RTDO) at the BC Children’s Hospital Research Institute to now offer grant facilitation support to WHRI members.  Our new grant facilitator, Amber Hui, has a Masters degree in Social and Personality Psychology from the City University of New […]

READ MORE
WHRI

BC population-based study examines the link between diabetes medications and the risk of endometrial cancer

It is well recognized that women with type 2 diabetes have an increased risk of endometrial (uterine) cancer.  There are various pharmacotherapy options for diabetes, including metformin and thiazolidinediones, which reduce insulin levels (insulin-sensitizing drugs), and secretagogues, which increase circulating insulin levels.  As hyperinsulinemia is recognized as a risk factor for the development of endometrial […]

READ MORE
Top
WHRI Menu
WHRI Menu